Cutaneous T-Cell Lymphoma Market Report 2026

The cutaneous t-cell lymphoma market size has grown strongly in recent years. It will grow from $2.72 billion in 2025 to $2.91 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to rare disease underdiagnosis, reliance on chemotherapy and radiation, limited treatment options, hospital-centered oncology care, delayed disease progression recognition.

The cutaneous t-cell lymphoma market size is expected to see strong growth in the next few years. It will grow to $3.78 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to advancements in targeted therapies, growth of precision oncology, increased disease awareness, expansion of specialty oncology clinics, improved diagnostic accuracy. Major trends in the forecast period include rising adoption of targeted immunotherapies, increased focus on early disease staging, growth of skin-directed treatment approaches, expansion of combination therapy regimens, improved long-term disease monitoring.

The growing burden of lymphoma cases is expected to drive the growth of the cutaneous T-cell lymphoma market in the coming years. Lymphoma is a type of cancer that originates in lymphocytes, a form of white blood cell found in the lymphatic system. The increase in lymphoma cases is associated with factors such as aging populations, environmental exposures, and genetic predisposition. Cutaneous T-cell lymphoma management supports lymphoma care by enabling accurate diagnosis and targeted treatment for patients whose disease primarily affects the skin, helping differentiate it from other lymphoma types and guiding appropriate therapeutic strategies. For instance, in October 2025, according to the American Cancer Society, a US-based nonprofit research organization, approximately 8,720 new cases of Hodgkin lymphoma were expected in the United States in 2025, including 4,840 males and 3,880 females. The organization also projected around 1,150 deaths, with 720 among males and 430 among females, indicating a sustained disease burden. Hodgkin lymphoma continues to be the most commonly diagnosed cancer among adolescents aged 15 to 19 years. Therefore, the increasing burden of lymphoma cases is contributing to the growth of the cutaneous T-cell lymphoma market.

Major companies operating in the cutaneous T-cell lymphoma market are focusing on the development of advanced treatment approaches, including therapies with targeted mechanisms of action that simultaneously address malignant T cells and immunosuppressive regulatory T cells. This dual-targeting strategy enables therapies to directly eliminate tumor cells while temporarily reducing regulatory T cells, thereby strengthening the body’s immune response against cancer. For example, in August 2024, a US-based pharmaceutical company received approval from the US Food and Drug Administration for LYMPHIR (denileukin diftitox-cxdl), representing a significant advancement in the treatment of relapsed or refractory cutaneous T-cell lymphoma. This novel therapeutic approach differentiates LYMPHIR from existing treatments and provides a new option for patients with relapsed or refractory disease.

In October 2025, Citius Oncology Inc., a US-based oncology therapeutics company, entered into a partnership with EVERSANA Inc. to support the planned fourth-quarter 2025 commercial launch of Lymphir, an FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma. Through this collaboration, Citius Oncology and EVERSANA aim to enhance commercial readiness, streamline market entry through integrated launch services, improve patient and healthcare provider access through coordinated medical, distribution, and reimbursement support, and strengthen long-term commercialization efficiency across the product lifecycle. EVERSANA Inc. is a US-based life sciences commercialization services company specializing in support for therapies targeting cutaneous T-cell lymphoma.

Major companies operating in the cutaneous t-cell lymphoma market are Merck & Co. Inc., Pfizer Inc., Bristol Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Eisai Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Actelion Pharmaceuticals Ltd., Soligenix Inc., Helsinn Healthcare SA, Innate Pharma SA, 4SC AG, Equillium Inc., Citius Pharmaceuticals Inc., Medivir AB, Amgen Inc., Roche Holding AG, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi, Regeneron Pharmaceuticals Inc.

North America was the largest region in the cutaneous T-cell lymphoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cutaneous t-cell lymphoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cutaneous t-cell lymphoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cutaneous t-cell lymphoma market by increasing costs of imported immunotherapy drugs, chemotherapy agents, diagnostic tools, and supportive care products. Hospitals and oncology clinics in North America and Europe are most affected due to reliance on imported specialty drugs, while Asia-Pacific faces higher treatment access costs. These tariffs are increasing therapy expenses. However, they are also encouraging domestic oncology drug development and regional manufacturing capabilities.

The cutaneous t-cell lymphoma market research report is one of a series of new reports that provides cutaneous t-cell lymphoma market statistics, including cutaneous t-cell lymphoma industry global market size, regional shares, competitors with a cutaneous t-cell lymphoma market share, detailed cutaneous t-cell lymphoma market segments, market trends and opportunities, and any further data you may need to thrive in the cutaneous t-cell lymphoma industry. This cutaneous t-cell lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cutaneous T-cell lymphoma is a rare form of cancer that affects T cells in the skin, resulting in symptoms such as rashes, tumors, and skin lesions. The most common subtypes are mycosis fungoides and Sézary syndrome. Patients often experience itching, skin thickening, and enlarged lymph nodes. Although the disease generally progresses slowly, advanced stages may spread to other organs.

The primary types of cutaneous T-cell lymphoma include mycosis fungoides and Sézary syndrome. Mycosis fungoides is a rare cancer in which specific white blood cells, known as T cells, become malignant and primarily involve the skin. Treatment options include radiation therapy, chemotherapy, immunotherapy, targeted therapy, and other approaches, and these treatments are provided across healthcare settings such as hospitals, diagnostic centers, and clinics.

The cutaneous T-cell lymphoma market includes revenues earned by entities by providing services such as skin biopsies, imaging studies, and molecular and genetic testing and related products such as topical corticosteroids, topical retinoids, and monoclonal antibodies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.